Advances leveraging artificial intelligence (AI) are reshaping drug discovery, diagnostics, and biomanufacturing. The Baker lab announced AI techniques to drug intrinsically disordered proteins previously deemed undruggable, expanding target space for therapeutics in pain, cancer, and metabolic diseases. Chemify opened a $16 million automated molecular design and synthesis facility integrating AI, computation, and robotics to accelerate next-gen drug and material discovery. 10x Genomics and A*STAR launched the TISHUMAP spatial transcriptomics collaboration, combining high-resolution tissue profiling with AI for drug target discovery in cancer. Biotx AI integrated GWAS data with ML to suggest drug targets and identify patient subpopulations. New AI-powered cell deconvolution tools like OmicsTweezer improve tumor tissue analysis. Meanwhile, digital twins and agentic AI are cutting-edge in optimizing biomanufacturing processes.